ArticleWorld journal of transplantation2026
Navigating the landscape of liver transplantation in neuroendocrine tumors: A comprehensive scoping review.
Article in World journal of transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroendocrine tumors (NET) are rare neoplasms with heterogeneous biological behavior. Although in these scenarios surgical resection can result in favorable outcomes, a considerable proportion of patients are not candidates for this modality due to extensive liver involvement. In these scenarios, liver transplantation (LT) may be a therapeutic alternative for these patients.
aimTo map the main evidence for the role of LT in NET. Analyze evidence and other possible therapies.
methodsA review of LT for hepatic metastatic NET. MEDLINE-PubMed, Lilacs, and Cochrane Library were searched. For MEDLINE-PubMed MESH-terms used were ["Neuroendocrine Tumors" (MeSH Terms)] OR "Neuroendocrine Tumors" (All Fields)] AND ["Liver Transplantation" (MeSH Terms) OR "Liver Transplantation" (All Fields)]. Cochrane Library search: ("neuroendocrine tumors" AND "liver transplantation"). Lilacs search: (neuroendocrine tumor) AND (liver transplantation). Articles were selected based on the person-centred care framework. Two independent reviewers (Oliveira EC, Zanini LK) performed selection and quality assessment, with a third (Nacif LS) resolving disagreements.
resultsAfter applying the inclusion and exclusion criteria based on the acronym person-centred care. A total of 73 articles out of 513 articles: 498 in MEDLINE, 12 in Cochrane, and 3 in LILACS. The last search was conducted in February 2025. No randomized controlled clinical trials or systematic reviews based on clinical trials were identified. We identified 14 reports or case series, 3 commentaries or letters to the editor, 22 retrospective cohorts, 29 narrative reviews, and 5 systematic reviews with diverse populations and based on observational studies.
conclusionLT may represent a significant benefit in overall survival for adult patients with liver metastases from NET who are not candidates for curative resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.